|
|
News Breaks | | | | December 20, 2012 | | 08:11 EDT |  | ACAD | ACADIA to get funding from Fast Forward, EMD Serono for MS program
ACADIA Pharmaceuticals announced that it will receive funding from Fast Forward, a not-for-profit organization established by the National Multiple Sclerosis Society, and EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany. This funding will support ACADIA research, to be conducted in collaboration with Dr. Rhonda Voskuhl of UCLA, directed at using AC-186, ACADIA’s proprietary and selective estrogen receptor-beta agonist, as a new approach to the treatment of multiple sclerosis. Fast Forward and EMD Serono will provide up to $545,000 to support preclinical studies with AC-186 designed to further evaluate pharmacokinetics and its therapeutic potential in preclinical models of MS. This funding will be provided by the parties’ Accelerating Commercial Development Fund, which is allocated to for-profit entities and is designed to accelerate the development of research discoveries into new or improved therapies for people with MS. | |
|
News For ACAD From The Last 14 Days Check below for free stories on ACAD the last two weeks. |
|
|
| May 15, 2013 | | 08:01 EDT |  | ACAD | ACADIA 8M share Spot Secondary priced at $12.50
 Subscribe for More Information | | | May 14, 2013 | | 16:01 EDT | | ACAD | ACADIA files to sell common stock, no amount given
Subscribe for More Information | |
|
|
|
|
|
|
